List of Excipients in Branded Drug PORTRAZZA

PORTRAZZA Excipient Strategy and Commercial Opportunities for Necitumumab

Last updated: September 24, 2026

Portrazza (necitumumab) is a recombinant IgG1 monoclonal antibody approved by the FDA in 2015 for use with gemcitabine and cisplatin in patients with metastatic squamous non-small cell lung cancer. Its commercial opportunity is now limited because U.S. marketing was discontinued, the indication was narrow, and the product required intravenous administration in a highly competitive oncology market. The strongest excipient opportunities are therefore formulation continuity, regional supply, hospital-use stability, and future necitumumab biosimilar or biobetter development rather than large-volume generic substitution.

What is Portrazza and how is it administered?

Portrazza contains necitumumab, a fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor, or EGFR. It was administered by intravenous infusion in combination with gemcitabine and cisplatin for first-line treatment of metastatic squamous NSCLC [1].

Attribute	Portrazza data
Active ingredient	Necitumumab
Product type	Recombinant monoclonal antibody
Antibody class	Human IgG1
Target	EGFR
Original developer	ImClone Systems and Eli Lilly
FDA application	BLA 125547
Dosage form	Intravenous solution
Strength	16 mg/mL
Vial presentation	800 mg in 50 mL
Administration	Intravenous infusion after dilution
Original indication	Metastatic squamous NSCLC
Combination regimen	Gemcitabine and cisplatin
FDA approval	November 13, 2015
Current U.S. commercial position	Discontinued marketing

The product was supplied as a sterile, preservative-free solution in a single-dose vial. The labeled preparation required dilution in 0.9% sodium chloride injection before administration [2].

What excipients are used in the Portrazza formulation?

Portrazza uses a conventional liquid monoclonal-antibody formulation based on buffering, tonicity control, surfactant protection, and water for injection.

The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Primary formulation function
Citric acid monohydrate	Acidic pH adjustment and buffer component
Sodium citrate dihydrate	Buffer capacity and pH control
Sodium chloride	Isotonicity adjustment
Polysorbate 80	Reduces interfacial stress and aggregation
Water for injection	Solvent

The formulation is designed to maintain antibody solubility during refrigerated storage, vial handling, transportation, dilution, and infusion. Polysorbate 80 is particularly important for limiting adsorption and agitation-induced aggregation, although it can generate degradation products such as peroxides and fatty acids over time. Those degradation pathways can affect monoclonal-antibody stability and may require tight control of excipient quality, oxygen exposure, storage temperature, and container closure performance.

The formulation does not rely on a lyophilized presentation. That reduces reconstitution steps but creates a larger dependence on cold-chain control and liquid-state stability.

What does the Portrazza label require for dilution and storage?

The label directs healthcare professionals to dilute the calculated dose in 0.9% sodium chloride injection. The diluted solution is administered by intravenous infusion over at least 60 minutes. The product is stored refrigerated, protected from light, and must not be frozen or shaken [2].

For an excipient supplier, the practical requirements are:

• Low-peroxide polysorbate 80 suitable for biologics.
• Tight control of trace metals and oxidation catalysts.
• Low bioburden and low endotoxin excipient grades.
• Consistent citrate buffer composition.
• Compatibility with glass vials, elastomer closures, transfer devices, infusion bags, and administration sets.
• Demonstrated stability after dilution in normal saline.

Which excipients create the largest commercial opportunities?

The largest opportunity is not a direct Portrazza generic. It is supply and formulation support for necitumumab products that use the reference product as a development benchmark.

Polysorbate 80

Polysorbate 80 is the most commercially significant excipient in the Portrazza formulation. It protects the antibody against surface-induced aggregation during manufacturing, filling, shipping, dilution, and infusion.

Potential supplier opportunities include:

1. Low-peroxide polysorbate 80.
2. Hydrolytically stable polysorbate 80 grades.
3. Single-use manufacturing-compatible grades.
4. Analytical packages covering peroxide, fatty-acid profile, water content, and degradation products.
5. Alternative surfactants such as polysorbate 20 or poloxamer 188 for future formulations.

A biosimilar developer would need to determine whether the reference product’s aggregation, subvisible particle, charge-variant, and potency profiles can be matched using the same surfactant or whether a different surfactant provides a more stable product.

Citrate buffer

Citrate is a familiar buffer for monoclonal antibodies, but it can contribute to pain on injection or infusion in some formulations and may interact with protein stability depending on pH and concentration.

Commercial opportunities include:

• Ready-to-use citrate buffer concentrates.
• Low-metal citrate raw materials.
• Custom buffer systems for biosimilar comparability.
• Alternative histidine or acetate systems for a reformulated necitumumab product.
• Buffer optimization to improve high-concentration stability or reduce infusion-related effects.

A reformulated product would need to demonstrate that changes in buffer species or pH do not alter aggregation, glycosylation, charge variants, potency, immunogenicity, or pharmacokinetics.

Sodium chloride

Sodium chloride is a low-value commodity excipient but remains important for tonicity and dilution compatibility. Its commercial value is tied to quality qualification rather than price.

The relevant procurement requirements are pharmaceutical grade, low endotoxin, validated elemental impurity control, and compatibility with the final container and infusion diluent.

How does Portrazza compare with competing EGFR antibody products?

Portrazza entered a market dominated by targeted therapies with oral dosing, broader biomarker-defined populations, and established treatment pathways. Its clinical use was restricted to squamous NSCLC and required combination chemotherapy.

Product	Active agent	Target	Route	Commercial positioning
Portrazza	Necitumumab	EGFR	IV infusion	Squamous NSCLC with gemcitabine and cisplatin
Erbitux	Cetuximab	EGFR	IV infusion	Colorectal cancer and head and neck cancer
Vectibix	Panitumumab	EGFR	IV infusion	RAS wild-type colorectal cancer
Tagrisso	Osimertinib	EGFR mutation	Oral	EGFR-mutated NSCLC
Iressa	Gefitinib	EGFR mutation	Oral	EGFR-mutated NSCLC
Tarceva	Erlotinib	EGFR mutation	Oral	EGFR-mutated NSCLC

Portrazza’s excipient strategy therefore cannot be assessed independently from its clinical and commercial positioning. An injectable EGFR antibody has higher manufacturing and administration costs than oral EGFR tyrosine kinase inhibitors. That weakens the commercial case for a standalone reformulation unless the product gains a new indication, a lower-cost biosimilar supply model, or a differentiated delivery profile.

What biosimilar opportunities exist for necitumumab?

Necitumumab is a biologic and would require a biosimilar pathway rather than an abbreviated new drug application. In the United States, a future developer would likely pursue a 351(k) application supported by analytical similarity, pharmacokinetic data, immunogenicity assessment, and clinical evidence appropriate to the product and indication [3].

The main formulation barriers are:

• Matching the reference product’s aggregation profile.
• Reproducing potency against EGFR.
• Controlling glycosylation and Fc-mediated functions.
• Demonstrating stability with polysorbate 80.
• Establishing comparable subvisible and visible particle levels.
• Showing compatibility with the labeled dilution and infusion process.
• Managing container-closure and extractables/leachables risks.
• Establishing a commercially viable cold-chain shelf life.

A biosimilar developer could use the Portrazza formulation as the initial reference point but would not necessarily need to duplicate every excipient concentration if the final product remains highly similar and clinically acceptable. Excipients that alter protein conformation, aggregation, or immunogenicity would receive greater scrutiny than inactive ingredients with limited product interaction.

What formulation patents protect Portrazza?

Portrazza’s core protection is expected to have centered on necitumumab antibody composition, anti-EGFR binding characteristics, manufacturing methods, and therapeutic uses. The U.S. Orange Book is not the principal source for biologic patent listings because biologics approved under a BLA are generally tracked through the Purple Book and related patent-exchange procedures rather than conventional small-molecule Orange Book listings [3,4].

The commercial relevance of any remaining patent estate depends on:

• Antibody sequence claims.
• Claims covering specific EGFR epitopes.
• Antibody production cell lines.
• Glycosylation or Fc-engineering claims.
• Combination-treatment claims.
• Dosing and administration claims.
• Liquid formulation claims.
• Regional patent term adjustments and extensions.
• Patent litigation or settlement activity in the target market.

No broad small-molecule-style generic substitution pathway exists for necitumumab. A competitor would need to assess the biologic patent estate, regulatory exclusivity history, trade-secret exposure, manufacturing know-how, and freedom to operate in each jurisdiction.

When did Portrazza lose regulatory and commercial exclusivity?

The key exclusivity milestones are:

Event	Timing
FDA approval	November 2015
Biologic reference-product exclusivity	Generally 12 years from first licensure under U.S. law, subject to statutory interpretation and product-specific analysis
U.S. commercial discontinuation	Eli Lilly discontinued commercial availability after limited market uptake
Biosimilar pathway	351(k) pathway available after applicable exclusivity barriers
Patent expiry	Patent-specific and jurisdiction-specific; not determined solely by FDA approval date

Regulatory exclusivity and patent protection are separate. A product may have no remaining regulatory exclusivity but still face patent barriers. Conversely, patent expiry does not guarantee immediate biosimilar launch because manufacturing, litigation, interchangeability, reimbursement, and supply issues remain.

What generic-entry risks exist for Portrazza?

The traditional generic-entry risk is low because Portrazza is a biologic. The more relevant risk is biosimilar or follow-on entry.

Low-risk areas

• No conventional ANDA substitution.
• Narrow original indication.
• Discontinued U.S. commercial presence.
• Limited reimbursement momentum.
• Competition from oral EGFR therapies and other immuno-oncology regimens.

Higher-risk areas

• A biosimilar developer obtains a lower-cost manufacturing process.
• A regional manufacturer supplies necitumumab outside the United States.
• A sponsor develops a more stable liquid formulation.
• A product uses a lower-cost surfactant or improved container system.
• A new clinical use expands the eligible patient population.
• A combination regimen improves clinical adoption.

A successful follow-on product would need a clear economic advantage. Lower drug acquisition cost alone may be insufficient if the treatment pathway, infusion infrastructure, and clinical preference have moved away from necitumumab.

What licensing and manufacturing opportunities exist?

Potential commercial opportunities fall into four categories.

Excipient supply

Excipient companies can supply polysorbate 80, citrate systems, sodium chloride, and formulation-development services. The strongest differentiation is analytical control and biologics stability data, not commodity pricing.

Biosimilar development

A company with an established mammalian-cell manufacturing platform could evaluate necitumumab as a portfolio asset. The opportunity is more credible in markets where the product remains registered, reimbursed, or clinically used.

Contract development and manufacturing

CDMOs could offer:

• Cell-line development.
• Upstream and downstream process development.
• Formulation screening.
• Sterile fill-finish.
• Stability studies.
• Comparability packages.
• Vial and infusion compatibility testing.

Reformulation or biobetter development

A new product could seek improved storage, reduced aggregation, lower infusion burden, or a more convenient presentation. Examples include a higher-concentration liquid, a prefilled infusion container, or a formulation with improved surfactant stability. Each change would require regulatory bridging and may create new patentable subject matter.

What is the commercial outlook for Portrazza excipients?

The commercial outlook is niche and technical rather than volume-driven.

Opportunity	Market attractiveness	Main constraint
Reference-product excipient supply	Low to moderate	Product discontinuation
Necitumumab biosimilar formulation	Moderate in selected regions	Narrow indication and weak demand
Low-peroxide polysorbate 80	Moderate to high across biologics	Competitive supplier market
Citrate buffer supply	Low for Portrazza alone	Commodity economics
CDMO formulation services	Moderate	Need for validated antibody platform
Reformulated necitumumab	Low to moderate	Clinical and commercial repositioning
Regional licensing	Market-specific	Registration and reimbursement status

The best investment thesis is a platform strategy built around monoclonal-antibody excipients, not Portrazza-specific volume. Polysorbate 80 quality, oxidation control, container compatibility, and liquid biologic stability apply to many commercial antibodies. Necitumumab can function as a development case study or regional product opportunity, but it is unlikely to support a large dedicated excipient manufacturing program.

Key Takeaways

• Portrazza contains necitumumab, a fully human IgG1 anti-EGFR antibody.
• The labeled formulation uses citrate buffer, sodium chloride, polysorbate 80, and water for injection.
• Polysorbate 80 is the most strategically important excipient because of its role in aggregation control and liquid stability.
• The product was approved for metastatic squamous NSCLC with gemcitabine and cisplatin.
• U.S. commercial discontinuation materially reduces direct Portrazza excipient demand.
• Future competition would arise through biosimilars or follow-on biologics, not conventional generics.
• The strongest commercial opportunity is a broader biologics excipient platform with necitumumab as one potential development target.
• Patent analysis must focus on biologic patent claims, formulation claims, manufacturing rights, and regional freedom to operate rather than the standard Orange Book framework.

FAQs

Is Portrazza a small-molecule drug or a biologic?

Portrazza is a biologic monoclonal antibody. Its active ingredient, necitumumab, is a recombinant human IgG1 antibody directed against EGFR.

What is the main excipient in Portrazza?

Portrazza uses polysorbate 80 as its principal surfactant. The formulation also contains citrate buffer, sodium chloride, and water for injection.

Can a generic company make a standard ANDA for Portrazza?

No. A conventional ANDA is not the normal pathway for a monoclonal antibody. A follow-on developer would generally need to pursue a biosimilar or other biologic approval pathway.

Could Portrazza be reformulated as a subcutaneous injection?

A subcutaneous version would require substantial development. Necitumumab concentration, viscosity, injection volume, absorption, immunogenicity, and local tolerability would all need evaluation.

Is there a strong commercial market for Portrazza excipients?

The product-specific market is limited because U.S. commercial availability was discontinued and the original indication was narrow. The broader market for polysorbate 80, citrate systems, and liquid monoclonal-antibody formulation services remains commercially relevant.

References

1. U.S. Food and Drug Administration. (2015). FDA approves Portrazza for metastatic squamous non-small cell lung cancer.
2. U.S. Food and Drug Administration. (2020). Portrazza (necitumumab) prescribing information. Eli Lilly and Company.
3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. Eli Lilly and Company. (2019). Annual report.